Latest news
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - StocktwitsStocktwits · Sat, 08 Aug 2026 06:32:17 GMTZentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:18:56 GMTMorgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 09:32:24 GMTZentalis Highlights Q2 Results and Azenosertib Progress - TipRanksTipRanks · Thu, 06 Aug 2026 21:11:51 GMTZentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMTZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 20:05:00 GMTPress Release: Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - MoomooMoomoo · Thu, 06 Aug 2026 20:05:00 GMTBlackRock (NYSE: BLK) discloses 5.2% ownership in Zentalis Pharmaceuticals (ZNTL) - Stock TitanStock Titan · Thu, 30 Jul 2026 07:00:00 GMT